A Phase 1b Dose Escalation/Dose Expansion Study of Icapamespib (PU-AD) in Patients with Recurrent Malignant Glioma
MD Anderson Study Status
This is a 2-part multicenter Phase 1b study designed to test icapamespib in patients with recurrent brain lesions. Part 1 of the trial will be a standard 3 by 3 dose escalation design where different doses are examined. Part 2 will be a dose expansion cohort to further evaluate the recommended Phase 2 dose (RP2D). The RP2D is defined as the dose level recommended for further clinical study, or the highest dose tested.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma, Grade 3 or 4 Astrocytoma, Glioblastoma Surgery
For general questions about clinical trials: